Commercialization of the Regenerative and Cell Medicine Value Chain
First written in FY2017-Q1. 10 of 20 entries say "Restated". Latest entry: 2026-05-13.
No other company in this theme has enough history to compare yet.
- 2026-05-13AdvancedEarnings
「In the CDMO business, we recognized revenue from a technology-transfer upfront fee in connection with progress in the technology transfer for contract manufacturing of a new investigational product from T Cell Nouveau Co., Ltd.」
The company reported concrete progress in expanding the cell-processing business, including the value-chain business, through a new CDMO project and the recognition of revenue from a technology-transfer upfront fee. - FY2025AdvancedAnnual report
「In the value-chain business, although one facility reached the end of its contracted facility operations and management period, net sales reached ¥80 million, up 35.6% year on year, due to royalty income from Medigen and sales of medical devices.」
In the value-chain business, royalty income from Medigen and medical device sales were generated, resulting in net sales of ¥80 million, up 35.6% year on year. - FY2025-H1AdvancedAnnual report
「Net sales increased to ¥404 million, up 1.3% year on year, as net sales from the value-chain business reached ¥52 million, up 85.6% year on year.」
In the value-chain business, net sales reached ¥52 million, up 85.6% year on year, due to royalty income from Medigen and sales of medical devices, among other factors. - FY2024-Q2RestatedAnnual report
「In the cell-processing business, we are actively pursuing initiatives to expand its three business areas: specified cellular product manufacturing, the CDMO business and the value-chain business.」
The company continues to pursue expansion in the three areas of specified cellular product manufacturing, the CDMO business and the value-chain business. - FY2023RestatedAnnual report
「Going forward, in addition to accepting contracts to process somatic cells and cells using somatic stem cells, among others, the Company will provide total solutions through the value-chain business that deliver a one-stop regenerative and cellular medicine value chain spanning research, development, manufacturing and marketing, thereby providing various forms of support so that customers can implement regenerative and cellular medicine smoothly.」
The Company continues to pursue expansion of the scope of its contract cell-processing services and one-stop value-chain support spanning research through marketing. - FY2023-Q3RestatedAnnual report
「The Company is actively pursuing initiatives to expand the three business areas of its cell processing business: specified cell processing products manufacturing, the CDMO business and the value-chain business.」
The Company continues to pursue its goal of expanding its business through the three areas of the cell processing business. - FY2022AdvancedAnnual report
「During the fiscal year, sales in the value-chain business increased due to higher transaction volumes in regenerative medicine-related services, although」
Regarding the commercialization of the value-chain business, the Company describes specific progress in the form of higher transaction volumes and sales from regenerative medicine-related services. - FY2022-Q3AdvancedAnnual report
「During the nine-month period ended the third quarter, net sales increased due to higher transaction volumes in the value-chain business, which provides regenerative medicine-related services.」
Regarding the commercialization of the value-chain business, the Company describes an increase in transactions and higher sales from regenerative medicine-related services. - FY2022-Q2RestatedAnnual report
「細胞加工業については、細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
The Company continues to pursue a policy of expanding its business through the three areas of the cell processing business, including the value-chain business. - FY2021-Q3RestatedAnnual report
「細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
The Company continues to pursue a policy of expanding the three areas of the cell processing business, including the value-chain business. - FY2021-Q2RestatedAnnual report
「細胞加工業については、細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
The Company continues to pursue a policy of expanding the three areas of the cell processing business, including the value-chain business. - FY2021-Q1RestatedAnnual report
「細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
The Company continues to pursue a policy of expanding the three areas of the cell processing business, including the value-chain business. - FY2020-Q3RestatedAnnual report
「細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
The Company continues to pursue a policy of commercializing and expanding the value-chain business through the three areas of the cell processing business. - FY2019-Q2RestatedAnnual report
「細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
The Company continues to pursue a policy of expanding its business through the three areas of the cell processing business. - FY2018-Q2RestatedAnnual report
「Although the Company has been steadily converting efforts to expand the monetization of the value-chain business, including contracted installation, operations and management of cell culture processing facilities and contracted technology development for cell processing, into orders」
The Company continues to monetize the value-chain business and win orders through facility operations and management, contracted technology development and related services. - FY2018-Q1AdvancedAnnual report
「In the cell processing business, the Company has strengthened its sales function and conducted broad sales activities to win contracts for the manufacture of specified cell processing products and regenerative medicine products, while working to expand the monetization of the value-chain business through contracted installation, operations and management of cell culture processing facilities and contracted technology development for cell processing, steadily converting these efforts into orders. However, sales of the core specified cell processing products declined due mainly to a decrease in the number of patients at contracted medical institutions. Net sales were ¥294 million, down ¥157 million, or 34.8%, year on year, and the segment loss was ¥135 million, compared with a segment loss of ¥86 million in the same period of the previous year.」
The Company states that sales activities for the value-chain business, including facility operations and management and contracted technology development, are being converted into orders. - FY2017AdvancedAnnual report
「By providing these services to medical institutions, the Company Group seeks to contribute to the wider adoption and development of regenerative and cellular medicine and the treatment of intractable diseases, while expanding its business.」
The Company continues to pursue a policy of expanding the value-chain business by providing consulting, facility operations and management, and engineering personnel dispatch and training, among other services. - FY2017-Q3AdvancedAnnual report
「また、収益拡大をすべく、再生・細胞医療のバリューチェーン事業化を目指し、再生・細胞医療のコンサルティング、細胞培養加工施設の運営管理、細胞加工技術者の派遣・教育システムの提供等を行っております。」
The Company states that it is continuing initiatives to commercialize the value-chain business and that the number of contracted projects, including facility operations and management and contracted technology development, has increased. - FY2017-Q2AdvancedAnnual report
「While projects in the value-chain business, including contracts to install and operate cell culture processing facilities and contracts for cell-processing technology development, increased substantially, sales of the comprehensive immune-cell therapy service to medical institutions declined slightly year on year. As a result, net sales were ¥893 million, down ¥25 million year on year.」
The Company describes significant progress in the commercialization of the value-chain business, including a substantial increase in projects involving facility operations and management and contracted technology development. - FY2017-Q1First statedAnnual report
「We have set the commercialization of the regenerative and cellular medicine value chain as a goal and are working to expand our business scope and earnings capacity.」
The goal is to commercialize a value chain covering consulting, technology transfer, process development, materials and equipment supply, cell storage and freezing, and cell transportation.